SARS-COV-2 Main Protease Inhibition by Bryophyllum Pinatum Phytochemicals: Computational and Kinetics Studies.

References

[1] Abbott, N. J. (2013). Blood–brain barrier structure and function and the challenges for CNS drug delivery. Journal of inherited metabolic disease, 36, 437-449.

[2] Adem, S., Eyupoglu, V., Sarfraz, I., Rasul, A., & Ali, M. (2020). Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA. Preprints, 2020, 2020030333.

[3] Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., ... & Mardinoglu, A. (2020). Current status of COVID-19 therapies and drug repositioning applications. Iscience, 23(7).

[4] Blanco-Melo, D., Nilsson-Payant, B. E., Uhl, S., Escudero-Pèrez, B., Olschewki, S., Thibault, P., ... & tenOever, B. R. (2020). An inability to maintain the ribonucleoprotein genomic structure is responsible for host detection of negative-sense RNA viruses. bioRxiv, 2020-03.

[5] Boonstra, A. M., Stewart, R. E., Köke, A. J., Oosterwijk, R. F., Swaan, J. L., Schreurs, K. M., & Schiphorst Preuper, H. R. (2016). Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Frontiers in psychology, 7, 1466.

[6] Chen, S., Yang, J., Yang, W., Wang, C., & Bärnighausen, T. (2020). COVID-19 control in China during mass population movements at New Year. The Lancet, 395(10226), 764-766.

[7] Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., ... & Edwards, D. K. (2021). Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature medicine, 27(11), 2025-2031.

[8] Doogue, M. P., & Polasek, T. M. (2013). The ABCD of clinical pharmacokinetics. Therapeutic advances in drug safety, 4(1), 5-7.

[9] Engkvist, O., Mervin, L. H., Chen, H., & Ran, T. (2023). Machine Learning in Drug Design.

[10] FDA. 2020. Fraudulent Coronavirus Disease 2019 (COVID-19) Products.https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-...

[11] Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., ... & Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583(7816), 459-468.

[12] Gupta, A., Li, P. K. T., Szeto, C. C., Piraino, B., Bernardini, J., Figureueiredo, A. E.,. & Struijk, D. G. (2010). Peritoneal dialysis-related infections recommendations: 2010 update. Peritoneal Dialysis International, 30(4), 393-423.

[13] Huang, J., & MacKerell Jr, A. D. (2013). CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data. Journal of computational chemistry, 34(25), 2135-2145.

[14] Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., ... & Yang, H. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289-293.

[15] Kumar, D., Chandel, V., Raj, S., & Rathi, B. (2020). In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach. Chemical Biology Letters, 7(3), 166-175.

[16] Kumar, S., & Saxena, S. K. (2021). Structural and molecular perspectives of SARS-CoV-2. Methods (San Diego, Calif.), 195, 23.

[17] Kumari, R., Kumar, R., Open Source Drug Discovery Consortium, & Lynn, A. (2014). g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. Journal of chemical information and modeling, 54(7), 1951-1962.

[18] Kuzikov, M., Morasso, S., Reinshagen, J., Wolf, M., Monaco, V., Cozzolino, F., ... & Zaliani, A. (2023). Resolving the pharmacological redox-sensitivity of SARS-CoV-2 PLpro in drug repurposing screening enabled identification of the competitive GRL-0617 binding site inhibitor CPI-169. bioRxiv, 2023-10.

[19] Lai, C. C., Liu, Y. H., Wang, C. Y., Wang, Y. H., Hsueh, S. C., Yen, M. Y., ... & Hsueh, P. R. (2020). Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection, 53(3), 404-412.

[20] Martins Fernandes Pereira K, Calheiros de Carvalho A, André Moura Veiga T, Melgoza A, Bonne Hernández R, Dos Santos Grecco S, Uchiyama Nakamura M, Guo S. The psychoactive effects of Bryophyllum pinnatum (Lam.) Oken leaves in young zebrafish. PLoS One. 2022 Mar 9;17(3):e0264987. doi: 10.1371/journal.pone.0264987. PMID: 35263358; PMCID: PMC8906576.

[21] Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., ... & Carrondo, M. A. (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor: implications for pathogenic gene mutations. Journal of Biological Chemistry, 275(34), 26164-26171.

[22] Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of medicinal chemistry, 58(9), 4066-4072.

[23] Rahman, M. M., Islam, M. R., Akash, S., Mim, S. A., Rahaman, M. S., Emran, T. B., ... & Wilairatana, P. (2022). In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective. Frontiers in Cellular and Infection Microbiology, 12, 929430.

[24] Ranard, L. S., Fried, J. A., Abdalla, M., Anstey, D. E., Givens, R. C., Kumaraiah, D., ... & Masoumi, A. (2020). Approach to acute cardiovascular complications in COVID-19 infection. Circulation: Heart Failure, 13(7), e007220.

[25] Senapati, S., Banerjee, P., Bhagavatula, S., Kushwaha, P. P., & Kumar, S. (2021). Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19. Journal of genetics, 100, 1-16.

[26] Shahbazi, S., Sahrawat, T. R., Ray, M., Dash, S., Kar, D., & Singh, S. (2016). Drug targets for cardiovascular-safe anti-inflammatory: In silico rational drug studies. PloS one, 11(6), e0156156.

[27] Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., ... & Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807), 221-224.

[28] Sharma, A., Bhatt, N. S., St Martin, A., Abid, M. B., Bloomquist, J., Chemaly, R. F., ... & Shah, G. L. (2021). Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology, 8(3), e185-e193.

[29] Sohrabi, C., Alsafi, Z., O'neill, N., Khan, M., Kerwan, A., Al-Jabir, A., ... & Agha, R. (2020). World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International journal of surgery, 76, 71-76.

[30] Souza, M. D. A., Souza, H. C. A., Viana, E. K. A., Alves, S. K. S., Sousa, C. S., Ribeiro, A. S. N., ... & Rocha, J. A. (2023). An In-silico Analysis Study of the Chemical Compounds from the Crassulaceous Plant Bryophyllum pinnatum (Lam.) Oken against the SARS-COV-2 Proteases. Journal of Advances in Medicine and Medical Research, 35(23), 69-91.

[31] Struyf, T., Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Leeflang, M. M., ... & Cochrane COVID-19 Diagnostic Test Accuracy Group. (2022). Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID‐19. Cochrane database of systematic reviews, (5).

[32] Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2), 455-461.

[33] Van der Spoel, D., van Maaren, P. J., & Caleman, C. (2012). GROMACS molecule & liquid database. Bioinformatics, 28(5), 752-753.

[34] Wang, B., Li, R., Lu, Z., & Huang, Y. (2020). Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (albany NY), 12(7), 6049.

[35] Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., ... & Ho, D. D. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5. Nature, 608(7923), 603-608.

[36] Wang, Q., Li, B., Xiao, T., Zhu, J., Li, C., Wong, D. F., & Chao, L. S. (2019). Learning deep transformer models for machine translation. arXiv preprint arXiv:1906.01787.

[37] Wang, X., Shen, Y., Wang, S., Li, S., Zhang, W., Liu, X., ... & Li, H. (2017). PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic acids research, 45(W1), W356-W360.

[38] Wells, M. L., Trainer, V. L., Smayda, T. J., Karlson, B. S., Trick, C. G., Kudela, R. M., ... & Cochlan, W. P. (2015). Harmful algal blooms and climate change: Learning from the past and present to forecast the future. Harmful algae, 49, 68-93.

[39] Weng, L. M., Su, X., & Wang, X. Q. (2021). Pain symptoms in patients with coronavirus disease (COVID-19): a literature review. Journal of Pain Research, 147-159.

[40] WHO. 2020. Coronavirus Disease (COVID-19) Advice for the Public: Myth Busters. Can Eating Garlic Help Prevent Infection with the New Coronavirus? https://www.who.int/images/default-source/health-topics/coronavirus/myth...

[41] Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., … Huang, Z. (2020). Computational Approaches in Preclinical Studies on Drug Discovery and Development. Frontiers in Chemistry, 8. doi:10.3389/fchem.2020.00726

[42] Zakharova, A. (2020). Chimera patterns in networks. Springer.

[43] Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., ... & Liang, T. (2020). Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. bmj, 369.

@article{1713852,
      author = {Iheanyichukwu Wopara, Emerike K. Kalu, Steve I. Omeodu, Shola D. Omoseeye, Felicia N. Okwakpam; Idowu O. Omotuyi},
      title = {SARS-COV-2 Main Protease Inhibition by Bryophyllum Pinatum Phytochemicals: Computational and Kinetics Studies.},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {7},
      pages = {2833-2847},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1713852.pdf},
      abstract = {Background: The newly discovered coronavirus infection emerged in Wuhan, China in December 2019 and since then, there has been no FDA approved drugs used in the treatment of corona virus infection, presenting a major challenge to medicine. The protease enzyme in SARS-CoV-2 virus can be a target for the production drugs to manage COVID-19 because of its indispensable role in the replication of the virus. 
Results: A total of 102 phytochemicals were identified in Bryophyllum pinnatum any of which could be a potential inhibitor of 3CLpro. These 102 phytochemicals were screened by molecular docking for their binding energies, 3,6-diglucosylapigenin was chosen as lead compound after meeting all the ADMETox qualifications using quikprop software. 3,6-diglucosylapigenin with a binding energy of -10.59Kj/mol shows a good inhibitory activity similar to 3CLpro standard inhibitor; boceprevir. The amino acid interaction between the lead compound and the active site of the protease were examined. MD simulation was performed to analyse Root mean square fluctuation (RMSF), Solvent Accessibility surface area (SASA) and number of hydrogen bond and the results reveled a strong affinity between the 3CLpro and the lead compound. Furthermore, the binding energy of the lead compound was stronger than that of the standard inhibitor. Moreso, the RMSF was decreased at the active site of the enzyme as there was no fluctuation. However, far away from the active site, there was very high fluctuation, opening the active site of the enzyme leading to escape of the ligand.
Conclusions: Ethanolic extract of Bryophyllum pinnatum was used for inhibiting the main protease of SARS-CoV-2 activity with the use of FRET assay to validate the study. Ethanol extracts from Bryophyllum pinnatum at 125.5µg/ml significantly inhibited 3CLpro activity at various concentrations of 100%, 50%, 30%, 10%, 3%, 0.3%, and 0.03%. This study identifies plant phytochemicals that can be a potential agent to combat COVID-19, and can eventually be used for future laboratory and clinical studies.
},
      keywords = {Sars-cov-2, main protease, Bryophyllum pinatum phytochemicals, RMSF and quikprop},
      month = {January},
      doi = {https://doi.org/10.64388/IREV9I7-1713852}
  }